Jazz Pharmaceuticals, Inc. First Quarter Earnings Sneak Peek

Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ) will unveil its latest earnings on Tuesday, May 8, 2012. Jazz Pharmaceuticals is a specialty pharmaceutical company, which is focused on developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.

Jazz Pharmaceuticals, Inc. Earnings Preview Cheat Sheet

Wall St. Earnings Expectations: The average estimate of analysts is for profit of 86 cents per share, a rise of 65.4% from the company’s actual earnings for the same quarter a year ago. During the past three months, the average estimate has moved down from 94 cents. Between one and three months ago, the average estimate moved down. It also has dropped from 89 cents during the last month. For the year, analysts are projecting net income of $3.91 per share, a rise of 24.9% from last year.

Past Earnings Performance: Last quarter, the company missed estimates by 5 cents, coming in at profit of 96 cents per share versus a mean estimate of net income of $1.01 per share. In the third quarter of the last fiscal year, the company beat estimates by 3 cents.

Investing Insights: What’s the Future of Microsoft’s Stock?

Wall St. Revenue Expectations: On average, analysts predict $102.5 million in revenue this quarter, a rise of more than twofold from the year-ago quarter. Analysts are forecasting total revenue of $489.2 million for the year, a rise of 79.7% from last year’s revenue of $272.3 million.

Analyst Ratings: Analysts are high on the stock, with five analysts rating it as a buy, none rating it as a sell and none rating it as a hold.

A Look Back: In the fourth quarter of the last fiscal year, profit rose 53.2% to $37.5 million (79 cents a share) from $24.5 million (61 cents a share) the year earlier, but fell short analyst expectations. Revenue rose 56.5% to $83.5 million from $53.4 million.

Key Stats:

With double-digit revenue growth the past four quarters, this earnings release is a chance to keep that positive trend going. The company has averaged year-over-year revenue growth of 56.1% over the last four quarters.

Stock Price Performance: Between April 26, 2012 and May 2, 2012, the stock price rose $6.31 (14%), from $45.20 to $51.51. The stock price saw one of its best stretches over the last year between June 13, 2011 and June 23, 2011, when shares rose for nine straight days, increasing 19% (+$5.10) over that span. It saw one of its worst periods between May 9, 2011 and May 17, 2011 when shares fell for seven straight days, dropping 11.1% (-$3.39) over that span.

(Company fundamentals by Xignite Financials. Earnings estimates provided by Zacks)

Don’t Miss These Additional Hot Stories:

Why Are These Health Stocks Feeling Under the Weather?

What Do Americans Think About Gold?>>

Here’s How to Bet on a Baby Boom>>